Invited to Present Phase 2 IPF and Chronic Cough Study Data There are numerous drugs with unrealized potential alongside many medical markets either being unmet or having only 1/2 extremely expensive/overpriced treatments. That's where $AGN.C comes in. $AGN.C is a company with a fairly unique approach. Rather than developing completely novel drugs for use, they find existing, safe, and proven compounds to repurpose for other treatments With various trials underway, the most recent phase 2 data shows a lot of potential.
- 65% improved vital capacity over the 40% from placebo trials. This means that their Ifenprodil treatment for IPF reached a positive level of statistical significance.
- The treatment of chronic cough found a decrease in cough counts by 32% at 4 weeks and 39.5% at 12. (also, some patients specially requested to keep the Ifenprodil for personal use).
- Ifenprodil showed no signs of causing any adverse effects and continues to be safe to use.
Plus, $AGN.C just got invited to present the data collected on the recently completed phase 2 study on IPF and chronic cough study at the 9th American Cough Conference. Health care professionals and industry pioneers focused on researching and managing patients with cough will attend the conference. With the recent data showing positive results for both the IPF and chronic cough tests, this is well deserved to be able to present their findings.
https://ca.finance.yahoo.com/news/algernon-pharmaceuticals-invited-present-phase-110700114.html
Overall, this company holds a lot of upside here. With the $25 price target, the $5.8M valuation is definitely an understatement of the company’s true value as they progress with trials and testing.